tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Moxey-Mims MM et al. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) 1998 Transplantation pmid:9521193
Mizunuma M et al. Role of calcineurin and Mpk1 in regulating the onset of mitosis in budding yeast. 1998 Nature pmid:9521328
Matsuda T et al. Immunosuppressants decrease neutrophil chemoattractant and attenuate ischemia/reperfusion injury of the liver in rats. 1998 J Trauma pmid:9529174
Briffa N and Morris RE Immunosuppressive drugs after lung transplantation. 1998 BMJ pmid:9529396
Venkataraman C et al. Activation of lyn, blk, and btk but not syk in CD72-stimulated B lymphocytes. 1998 J. Immunol. pmid:9531290
Walensky LD et al. The 13-kD FK506 binding protein, FKBP13, interacts with a novel homologue of the erythrocyte membrane cytoskeletal protein 4.1. 1998 J. Cell Biol. pmid:9531554
First MR Clinical application of immunosuppressive agents in renal transplantation. 1998 Surg. Clin. North Am. pmid:9531936
Corry RJ et al. Pancreas transplantation without antibody therapy. 1998 Transplant. Proc. pmid:9532050
Kahl A et al. First results with a quadruple therapy regimen including tacrolimus and mycophenolate mofetil in patients after combined pancreas and kidney transplantation. 1998 Transplant. Proc. pmid:9532149
Bruce DS et al. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9532150
Peddi VR et al. Tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9532151
Burke GW et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. 1998 Transplant. Proc. pmid:9532153
Büsing M et al. Mycophenolate mofetil/tacrolimus/single-shot versus azathioprine/cyclosporine/ATG in pancreas-kidney transplantation: results of a prospective randomized single-center study. 1998 Transplant. Proc. pmid:9532155
Gruessner RW et al. Mycophenolate mofetil and tacrolimus for induction and maintenance therapy after pancreas transplantation. 1998 Transplant. Proc. pmid:9532156
Corry RJ et al. Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. 1998 Transplant. Proc. pmid:9532157
Elmer DS et al. Metabolic effects of FK 506 (tacrolimus) versus cyclosporine in portally drained pancreas allografts. 1998 Transplant. Proc. pmid:9532159
Burke GW et al. Tacrolimus-related microangiopathy in kidney and simultaneous pancreas-kidney recipients: evidence of endothelin and cytokine involvement. 1998 Transplant. Proc. pmid:9532223
Ochiai M et al. Islet toxicity of FK506 measured in canine autografts. 1998 Transplant. Proc. pmid:9532224
Wiederrecht G and Siekierka JJ Yeast immunophilins: purification and assay of yeast FKBP12. 1998 Meth. Enzymol. pmid:9534152
Mattoo AK Peptidylprolyl cis-trans-isomerases from plant organelles. 1998 Meth. Enzymol. pmid:9534153
Cichon G and Strauss M Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer. 1998 Gene Ther. pmid:9536268
Schäffer MR et al. Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. 1998 Transplantation pmid:9539093
Anderson PO Tacrolimus and breastfeeding. 1998 Transplantation pmid:9539100
Hiroi J et al. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. 1998 Jpn. J. Pharmacol. pmid:9541280
Bassing CH et al. FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes. 1998 Cell Growth Differ. pmid:9543388
Lopez-Ilasaca M et al. Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. 1998 J. Biol. Chem. pmid:9545268
Matsuoka S et al. [Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence]. 1998 Rinsho Ketsueki pmid:9545827
Endrich MM and Gehring H The V3 loop of human immunodeficiency virus type-1 envelope protein is a high-affinity ligand for immunophilins present in human blood. 1998 Eur. J. Biochem. pmid:9546659
Trull AK Therapeutic monitoring of tacrolimus. 1998 Ann. Clin. Biochem. pmid:9547889
ten Berge RJ and Schellekens PT [Immunology in clinical practice. VI. Current immunosuppressive drugs]. 1997 Ned Tijdschr Geneeskd pmid:9550813
Epstein A et al. Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction. 1998 Surgery pmid:9551073
Matsuda T and Baba A [Response of Na+/Ca2+ antiporter to ischemia and glial/neuronal death]. 1998 Nippon Yakurigaku Zasshi pmid:9551468
Hashimoto T et al. [Involvement of calcineurin A alpha and A beta in neuronal death in a gerbil model of cerebral ischemia]. 1998 Nippon Yakurigaku Zasshi pmid:9551469
Wiederrecht GJ et al. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. 1995 Prog Cell Cycle Res pmid:9552353
Terashima A et al. Single-channel activity of the Ca2+-dependent K+ channel is modulated by FK506 and rapamycin. 1998 Brain Res. pmid:9555045
D'Incà R et al. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. 1998 Ann. Intern. Med. pmid:9556483
Antonysamy MA et al. Flt-3 ligand increases microchimerism but can prevent the therapeutic effect of donor bone marrow in transiently immunosuppressed cardiac allograft recipients. 1998 J. Immunol. pmid:9558122
Ku YM and Min DI An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. 1998 Ther Drug Monit pmid:9558138
Jubran RF and Dinndorf PA Successful therapy of refractory graft versus host disease with tacrolimus and Psoralen plus ultraviolet light. 1998 Ther Drug Monit pmid:9558141
Taylor PJ et al. Therapeutic drug monitoring of tacrolimus (FK506) using tandem mass spectrometry. 1998 Ther Drug Monit pmid:9558142
Main ER et al. Context-dependent nature of destabilizing mutations on the stability of FKBP12. 1998 Biochemistry pmid:9558354
Takaoka Y et al. Cyclosporin A and FK-506 inhibit development of superantigen-potentiated collagen-induced arthritis in mice. 1998 Gen. Pharmacol. pmid:9559334
Cicalese L et al. Phenotypic and functional characteristics of intestinal intraepithelial lymphocytes during acute rejection of small intestinal allografts. 1998 Transpl. Int. pmid:9561676
Fernández-Miranda C et al. Lipid abnormalities in stable liver transplant recipients--effects of cyclosporin, tacrolimus, and steroids. 1998 Transpl. Int. pmid:9561680
Jain A et al. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. 1998 Liver Transpl Surg pmid:9563957
Hayashi M et al. Allograft rejection after liver transplantation for autoimmune liver diseases. 1998 Liver Transpl Surg pmid:9563959
Yuzawa K and Fukao K Topical FK506 ointment for skin grafting. 1998 Transplantation pmid:9565111
Kennedy AP et al. Polyomavirus middle T antigen as a probe for T cell antigen receptor-coupled signaling pathways. 1998 J. Biol. Chem. pmid:9565564
Pizzolato GP et al. Cerebral vasculitis during FK 506 treatment in a liver transplant patient. 1998 Neurology pmid:9566415
Salerno A et al. The effect of cyclosporin A, FK506 and rapamycin on the murine contact sensitivity reaction. 1998 Clin. Exp. Immunol. pmid:9566798
Mollison KW et al. Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models. 1998 Toxicology pmid:9570331
Araki T et al. Post-ischemic alterations in [3H]FK506 binding in the gerbil and rat brains. 1998 Metab Brain Dis pmid:9570636
Finney NS Enantioselective epoxide hydrolysis: catalysis involving microbes, mammals and metals. 1998 Chem. Biol. pmid:9571210
Matsuda T et al. Involvement of calcineurin in Ca2+ paradox-like injury of cultured rat astrocytes. 1998 J. Neurochem. pmid:9572286
Barinaga M Signaling path may lead to better heart-failure therapies. 1998 Science pmid:9575084
Miyasaka N [Recent findings on etiological mechanism of autoimmune diseases]. 1998 Nippon Naika Gakkai Zasshi pmid:9577564
Sakane T [Physiopathology and therapy of Behcet's syndrome]. 1998 Nippon Naika Gakkai Zasshi pmid:9577569
Sugi-Ikai N et al. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease. 1998 Invest. Ophthalmol. Vis. Sci. pmid:9579479
Cardoso CM et al. Uncoupling of Ca2+ transport ATPase in muscle and blood platelets by diacylglycerol analogues and cyclosporin A antagonism. 1997 Biochem. J. pmid:9581558
Abu-Elmagd K et al. Clinical intestinal transplantation: new perspectives and immunologic considerations. 1998 J. Am. Coll. Surg. pmid:9583691
Zervos XA et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplantation pmid:9583863
Muraki T et al. Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. 1998 Transplantation pmid:9583878
Kadry Z et al. Kaposi's sarcoma in liver transplant recipients on FK506. 1998 Transplantation pmid:9583882
Chiba K et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. 1998 J. Immunol. pmid:9590253
Hebebrand D et al. Limb xenotransplantation using FK506 and RS61443 immunosuppression. 1998 J Reconstr Microsurg pmid:9590615
Wakita H et al. Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia. 1998 Brain Res. pmid:9593846
Marone G et al. Immunopharmacology of human mast cells and basophils. 1998 Int. J. Clin. Lab. Res. pmid:9594358
Weis M et al. Impact of immunosuppression on coronary endothelial function after cardiac transplantation. 1998 Transplant. Proc. pmid:9595131
Gregory CR Immunosuppressive approaches to the prevention of graft vascular disease. 1998 Transplant. Proc. pmid:9595134
Koyama T et al. [Effects of various drugs on IL-8 production by eosinophils collected from patients with allergic inflammation]. 1998 Jpn J Antibiot pmid:9597507
Wagner R et al. 32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency. 1998 J. Med. Chem. pmid:9599228
Hueros G et al. A maize FK506-sensitive immunophilin, mzFKBP-66, is a peptidylproline cis-trans-isomerase that interacts with calmodulin and a 36-kDa cytoplasmic protein. 1998 Planta pmid:9599809
Oyanagui Y Immunosuppressants enhance superoxide radical/nitric oxide-dependent dexamethasone suppression of ischemic paw edema in mice. 1998 Eur. J. Pharmacol. pmid:9600660
Jurcevic S et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. 1998 Transplantation pmid:9603168
Beatty PR et al. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. 1998 Transplantation pmid:9603175
Shapiro R et al. Alopecia as a consequence of tacrolimus therapy. 1998 Transplantation pmid:9603186
Capone D et al. Therapeutic monitoring of tacrolimus in pediatric and adult transplanted patients. 1998 J Chemother pmid:9603651
Chang RK et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. 1998 Am. J. Cardiol. pmid:9604971
Homey B et al. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. 1998 J. Immunol. pmid:9605132
Tomura N et al. Transient neurotoxicity associated with FK506: MR findings. 1998 May-Jun J Comput Assist Tomogr pmid:9606397
Tomono M et al. Inhibitors of calcineurin block expression of cyclins A and E induced by fibroblast growth factor in Swiss 3T3 fibroblasts. 1998 Arch. Biochem. Biophys. pmid:9606972
Singer NG and McCune WJ Update on immunosuppressive therapy. 1998 Curr Opin Rheumatol pmid:9608317
Ito H et al. Myoblast transplantation in non-dystrophic dog. 1998 Neuromuscul. Disord. pmid:9608563
Kliem V and Brunkhorst R Tacrolimus in kidney transplantation. A clinical review. 1998 Nephron pmid:9609456
Samsó M and Wagenknecht T Contributions of electron microscopy and single-particle techniques to the determination of the ryanodine receptor three-dimensional structure. 1998 J. Struct. Biol. pmid:9615436
Tomás ML [Immunosuppressive agents: side effects]. 1997 An R Acad Nac Med (Madr) pmid:9616947
Idilman R et al. Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant. 1998 Eur J Gastroenterol Hepatol pmid:9619393
Kikuchi M et al. Protective effects of FK506 against glutamate-induced neurotoxicity in retinal cell culture. 1998 Invest. Ophthalmol. Vis. Sci. pmid:9620083
Lampen A et al. Catalytic activities, protein- and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. 1998 Xenobiotica pmid:9622846
Schulman SL et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. 1998 Transplantation pmid:9625026
Pruvot FR and Noel C Comment on "Pregnancy after liver transplantation under tacrolimus" by Jain et al. 1998 Transplantation pmid:9625033
Takada Y et al. Prolonged hepatic warm ischemia in non-heart-beating donors: protective effects of FK506 and a platelet activating factor antagonist in porcine liver transplantation. 1998 Surgery pmid:9626320
Ellouk-Achard S et al. FK506 (Tacrolimus) decreases the cytotoxicity of cyclosporin A in rat hepatocytes in primary culture: implication of CYP3A induction. 1998 Arch. Toxicol. pmid:9630010
Starzl TE et al. Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. 1998 Am. J. Kidney Dis. pmid:9631858
Al-Awwa IA et al. Importance of allograft biopsy in renal transplant recipients: correlation between clinical and histological diagnosis. 1998 Am. J. Kidney Dis. pmid:9631859
Tredger JM et al. Therapeutic monitoring of tacrolimus (FK506) with the first- and second-generation microparticle enzyme immunoassays: performance and results in four patient populations. 1998 Ther Drug Monit pmid:9631923
Nicholson ML et al. Is TGF-beta a profibrotic cytokine in human renal transplants? 1998 Transplant. Proc. pmid:9636384
Ginevri F et al. Expression of collagen by renal fibroblasts treated with FK 506 in vitro. 1998 Transplant. Proc. pmid:9636387
Hutchinson IV et al. Differences in the mode of action of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636388
Müller V et al. Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney. 1998 Transplant. Proc. pmid:9636396